Showing 2641-2650 of 5618 results for "".
- Natural Speech Analysis: A Frontier in Cognitive Healthhttps://reachmd.com/news/natural-speech-analysis-a-frontier-in-cognitive-health/2484438/Researchers from Baycrest Hospital, the University of Toronto, and York University report that natural speech timing features can show cognitive shifts before standard tests, creati
- High-Flow Nasal Oxygen: An Effective Alternative in Anesthesia Inductionhttps://reachmd.com/news/high-flow-nasal-oxygen-an-effective-alternative-in-anesthesia-induction/2484380/A randomized non-inferiority trial in adults undergoing frame-based stereoelectroencephalography (SEEG) found that high-flow nasal oxygen (HFNO) provides effective oxygenation during anesthesia induction and offers a practical alternative to facemask ventilation when headframes limi
- FDA Approval of Tezepelumab for Chronic Rhinosinusitis with Nasal Polypshttps://reachmd.com/news/fda-approval-of-tezepelumab-for-chronic-rhinosinusitis-with-nasal-polyps/2484342/The FDA has approved tezepelumab-ekko for chronic rhinosinusitis with nasal polyps (CRSwNP) in patients 12 years
- Innovative Antibacterial Wound Dressings: Coaxial Electrospun Nanofibers with Shikonin and Cresolhttps://reachmd.com/news/innovative-antibacterial-wound-dressings-the-role-of-coaxial-electrospun-nanofibers-with-shikonin-and-cresol/2484280/Coaxial electrospun PVP nanofibers co‑delivering shikonin and cresol show retained antibacterial activity and a rapid burst‑release profile in vitro, supporting further translational evaluation
- Experimental Nanobody Shows Promise for Psoriatic Arthritis in Phase 2 Trialhttps://reachmd.com/news/experimental-nanobody-shows-promise-for-psoriatic-arthritis-in-phase-2-trial/2483875/A novel nanobody therapy targeting dual inflammatory pathways has shown encouraging results in treating psoriatic arthritis (PsA), a complex and disabling autoimmune disease. The investigational agent
- Dual-Targeting Nanobody Sonelokimab Shows Promise in Psoriatic Arthritis Phase 2 Trialhttps://reachmd.com/news/dual-targeting-nanobody-sonelokimab-shows-promise-in-psoriatic-arthritis-phase-2-trial/2483881/A novel nanobody therapy targeting dual inflammatory pathways has shown encouraging results in treating psoriatic arthritis (PsA), a complex and disabling autoimmune disease. The investigational agent,
- Unlocking Equitable Care: Navigating Healthcare Access and Innovative Practices in Obesity Managementhttps://reachmd.com/news/unlocking-equitable-care-navigating-healthcare-access-and-innovative-practices-in-obesity-management/2483579/The challenges of healthcare access perpetuate both stigma and delayed treatment, impacting metabolic health. Delays in imaging and specialty referrals can mean missed NAFLD screening, postponed diabetes management, and fewer opportunities for early intervention. Pat
- Dr. Anthony Brissett Named President of AAFPRS for 2025–2026 Termhttps://reachmd.com/news/dr-anthony-brissett-named-president-of-aafprs/2483515/Anthony E. Brissett, MD, FACS, a facial plastic and reconstructive surgeon based in Houston, has been named President of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) for the 2025–2026 term. His appointment was formalized during the AAFPRS Annual Business Meeting held
- Revolutionizing Lung Cancer Diagnosis: The Role of Robotic Navigational Bronchoscopyhttps://reachmd.com/news/revolutionizing-lung-cancer-diagnosis-the-role-of-robotic-navigational-bronchoscopy/2483449/As robotic navigational bronchoscopy steadily progresses, it is advancing lung cancer diagnosis, offering more consistent navigation to small, peripheral nodules under CT-guided workflows. In clinical practice, its use is considered within evolving ACCP/ATS/NCCN recommendations for evaluati
- Rethinking Risk: Navigating the Complexities of GG1 Prostate Cancerhttps://reachmd.com/news/rethinking-risk-navigating-the-complexities-of-gg1-prostate-cancer/2483467/Prostate cancer poses a common clinical challenge in urology, particularly around accurately assessing risk in Grade Group 1 (GG1) cases. The narrative begins with a practical realization: reevaluating risk in GG1 prostate cancer may reduce overtreatment and support more individuali